Off-the-Shelf Cell Therapies: Breaking Barriers and Revolutionizing Patient Care

In this episode of "Conversations in Drug Development", Harriet Edwards and Dr. Patrick Ginty discuss off-the-shelf cell therapies, explaining how these therapies are manufactured and their ability to treat multiple recipients. While these therapies offer scalability and the potential to treat larger patient populations, they also carry risks such as immune reactions. Dr. Ginty highlights the importance of addressing these risks and mentions techniques like gene editing to improve safety. Join us in this conversation as we discuss the regulatory challenges in developing these therapies, emphasizing the importance of early engagement with regulators and compliance with donor testing requirements.
 
To discuss this episode of Conversations in Drug Development with a member of the team, visit www.boydconsultants.com.